Verified facts — the pinned numbers
Every chapter in this curriculum draws its quantitative claims from this file. Nothing here was written from memory: each entry was checked against a source on the date shown.
Why this file exists. A 58-chapter textbook written over many sittings will — the gene count becomes 19,000 in one chapter and 20,000 in another, the is "47 genomes" in Chapter 43 and "200+" in Chapter 45. Pinning the numbers in one place makes that class of error impossible, and makes the whole knowledge base auditable: you can check this one file rather than re-reading 140,000 words.
How to use it when writing. Never state a number in a chapter that is not either (a) listed here, (b) derived from something listed here with the derivation shown, or (c) explicitly framed as an approximate teaching figure.
Confidence tiers
| Tier | Meaning | How to write it |
|---|---|---|
| A | Fetched directly from the primary source (database stats page, consortium site, published paper) | State the exact number, cite release/version |
| B | Confirmed across reputable secondary sources, primary not directly fetched | State the number, hedge lightly ("approximately") |
| C | Fast-moving vendor specification or an actively contested estimate | Give a range, name the date, tell the reader it moves |
Human genome — annotation
Source: GENCODE Human Release 50 statistics · fetched 2026-08-13 · Tier A
| Quantity | Value |
|---|---|
| Protein-coding genes | 19,442 |
| Long non-coding RNA genes | 35,885 |
| Small non-coding RNA genes | 7,608 |
| 14,702 | |
| — processed | 10,634 |
| — unprocessed | 3,535 |
| — unitary | 296 |
| — IG/TR pseudogenes | 237 |
| IG/TR protein-coding segments | 412 |
| Readthrough genes (protein-coding, not inside the 19,442) | 665 |
| Artifact biotype | 19 |
| Total annotated genes | 78,733 |
| Total transcripts | 644,292 |
The four pseudogene sub-counts are components of the 14,702, not additions to it: 10,634 + 3,535 + 296 + 237 = 14,702, exactly. The IG/TR row on GENCODE's page splits into 412 protein-coding segments and 237 pseudogenes; only the 412 sit outside the four headline categories, because the 237 are already counted as pseudogenes.
The non-coding count — do not compute it by subtraction
58,195, not 59,291. The four headline categories sum to 77,637, leaving 1,096 of the 78,733 total. That residual is routinely misidentified — including in an earlier version of this file — as immunoglobulin and T-cell-receptor gene segments alone. GENCODE's own rows decompose it exactly:
412 IG/TR protein-coding segments + 665 readthrough genes + 19 artifact = 1,096
1,077 of the 1,096 are protein-coding (the IG/TR segments plus the readthrough genes), so the teaching point survives intact: subtracting protein-coding genes from the total sweeps over a thousand coding entities into the non-coding tally. Only the identification of the residual changes.
Use 35,885 + 7,608 + 14,702 = 58,195. The ~3:1 non-coding:coding ratio survives either way, but the honest figure is 58,195.
Say which 3:1 you mean. 58,195 / 19,442 = 2.99:1 only because pseudogenes are in the numerator. Transcribed non-coding RNA genes alone are 35,885 + 7,608 = 43,493, i.e. 2.24:1. A sentence whose subject is "transcribed into non-coding RNA" must therefore say better than 2:1, and reach 3:1 only by explicitly adding the pseudogenes — which are the weakest part of the anti-junk argument anyway.
Teaching note. The protein-coding count is one of the most misquoted numbers in biology. The 2001 draft-genome estimates of 30,000–40,000 have been revised steadily downward; "about 20,000" is the honest round figure and 19,442 is the current . Note also that non-coding genes now outnumber coding genes roughly 3:1 — a fact that should be used to kill the "" framing in Chapters 03 and 39.
Human genome — composition
| Quantity | Value | Tier | Source |
|---|---|---|---|
| content | ~46% of the genome ( ) | B | T2T repeat-element analyses, Science 2022 |
| Sequence newly resolved by T2T-CHM13 | ~8% of the genome, previously inaccessible — all , and the entire short arms of five acrocentric | B | The complete sequence of a human genome, Science 2022 |
| Only autonomously active human TE | B | as above | |
| Alu copy number | ~1.1 million copies, ~11% of the genome | B | Alu elements: know the SINEs |
| 30 nm chromatin fibre compaction | ~40-fold cumulative relative to naked DNA — i.e. a further ~6-fold beyond the , not a further 40-fold | B | standard chromatin texts |
| Nucleosome-occupied fraction | ~75% of the genome on an octamer at any moment. The remainder is mostly linker, which is not accessible; ATAC/DNase-accessible regions are ~1–3% of the genome | B | ENCODE data |
Replication fidelity — mind the units
Tier B · DNA Replication — A Matter of Fidelity, Molecular Cell 201630140-X)
| Filter | Error rate after this step | Improvement |
|---|---|---|
| Polymerase base selection | ~10⁻⁵ | — |
| + 3′→5′ | ~10⁻⁷ | 10²–10³ |
| + | ~10⁻⁹ – 10⁻¹⁰ | 10²–10³ |
Final replication fidelity: ~10⁻¹⁰ per base per cell division (measured as low as 2 × 10⁻¹⁰ substitutions per base per division).
This is the single easiest unit error in the curriculum, and it appeared in four chapters and one problem set before being caught. Replication fidelity ~10⁻¹⁰ is per base per replication. The rate ~1.1–1.3 × 10⁻⁸ is per base per generation — a different quantity that sums hundreds of cell divisions and includes unrepaired chemical damage that was never a polymerase error. They differ by ~100× and are not comparable.
Sanity check, and note it overshoots: 10⁻¹⁰ × ~300 germline divisions ≈ 3 × 10⁻⁸ against a measured 1.2 × 10⁻⁸. Agreement within a factor of 2–3 is all this calculation is entitled to claim — 10⁻¹⁰ is an order-of-magnitude bound, not a constant.
Spontaneous DNA damage
| Process | Rate | Tier |
|---|---|---|
| Depurination (loss of A or G by spontaneous hydrolysis) | on the order of 10⁴ per cell per day | C — sources span ~5,000 to ~26,000 depending on what is counted; use the order of magnitude |
Germline mutation rate
Tier B · multiple trio and long-read studies
| Quantity | Value |
|---|---|
| Genome-wide SNV rate | ~1.1–1.3 × 10⁻⁸ per bp per generation |
| Recent long-read pedigree estimate | 1.30 × 10⁻⁸ per bp per generation |
| Coding-sequence rate | somewhat higher, ~1.25–2.1 × 10⁻⁸ |
| Fraction of of paternal origin | ~80% |
| Additional de novo mutations per year of paternal age | ~1.3–1.5 |
Use the rate to derive the ~60–70 de novo mutations per genome per generation figure in Chapter 16 rather than asserting it — the derivation is the teaching point.
Human generation time
Tier C · fetched 2026-08-13 · Wang RJ, Al-Saffar SI, Rogers J & Hahn MW, "Human generation times across the past 250,000 years", Science Advances 9:eabm7047, 2023 (PMID 36608127)
| Quantity | Value |
|---|---|
| Sex-averaged generation time, averaged over the past 250 kyr | 26.9 years |
| Paternal | 30.7 years |
| Maternal | 23.2 years |
Curriculum convention: 27 years per generation. Use it wherever generations are converted to years, and name it in the same sentence.
Tier C because this is a model-based inference from the spectrum rather than a measurement, and it is contested; the usable literature spans roughly 25–30 years, and older sources routinely use 25 or 29. Every years-from-generations conversion inherits that ±10% spread, so quote the generation count — which is exact — and treat the years as approximate.
This was a live inconsistency, not a hypothetical. Chapter 27 converted a 69,000-generation mutation half-life at 25 years (1.7 My); Chapter 29 converted a 6,900-generation LD half-life at 28 years (194,000 y). Both now use 27 years, giving 1.9 My and 190,000 y. The choice is not cosmetic: at 25 versus 29 years that LD half-life reads 173,000 or 200,000 years — the difference between "shorter than" and "comparable to" the 315 ± 34 kyr age of the oldest H. sapiens fossils (Hublin et al., Nature 546:289, 2017).
Molecular machinery — Part 1 chapters
Fetched from the primary sources on 2026-08-13, during the adjudicated accuracy pass. Each row replaced a number that was wrong or overstated in the text.
| Quantity | Value | Tier | Source |
|---|---|---|---|
| Pol III cores per active E. coli replisome | three, not the classical two — three τ molecules trimerise the polymerase. Purified holoenzyme is still often drawn as a dimer | A | Reyes-Lamothe, Sherratt & Leake, Science 328:498, 2010 |
| UP-element stimulation at E. coli rrnB P1 | ~30-fold (αCTD–UP element interaction reported at 30–70-fold in vivo; a consensus UP element in the wild-type position gives 29-fold). Not tenfold | A | Ross et al., Science 262:1407, 1993 · Meng et al., Nucleic Acids Res. 29:4166, 2001 |
| σ⁵⁴ activator (bacterial -binding protein) distance | 80–150 bp upstream of the in natural systems. Not "hundreds of base pairs" | B | Bush & Dixon, Microbiol. Mol. Biol. Rev. 76:497, 2012 |
| Minor (U12-type) snRNAs | Four unique — U11, U12, U4atac, U6atac — plus U5, which is shared with the major spliceosome. A parts list omitting U5 is incomplete | A | Pessa et al., PNAS 105:8655, 2008 — "U5 snRNA, in contrast, is shared between the two spliceosomes." |
Lactase persistence — timing, and what it does not show
Tier A · fetched 2026-08-13 · Evershed et al., Nature 608:336–345, 2022 (Europe PMC record)
| Quantity | Value |
|---|---|
| Strength of selection | LP is the most strongly selected monogenic trait to have evolved over the past 10,000 years (verbatim) |
| Earliest European LP individual in ancient DNA | c. 4,700–4,600 BC |
| First reaches appreciable frequency | c. 2,000 BC — "nearly three millennia after its first detection" |
| Milk use in Europe | widespread from the Neolithic onwards, i.e. long before the frequency rise |
Do not couple the sweep to the start of dairying. The paper's own model comparison rejects it: "LP selection varying with levels of prehistoric milk exploitation is no better at explaining LP trajectories than uniform selection since the Neolithic period." Population fluctuations, settlement density and wild-animal exploitation fit better, and the authors propose famine and/or increased pathogen exposure as what made lactase non-persistence costly. Write it as a very strong selection signal whose driver is still argued over — Chapter 00's worked example does exactly this.
Population reference datasets
| Resource | Current state | Tier | Source |
|---|---|---|---|
| Current release is v4.1.1 (30 March 2026) — a gene-, LOFTEE- and update on v4.1 (19 April 2024), which itself fixed v4.0's -number issue. The cohort is unchanged since v4.0 (1 November 2023): 730,947 exomes + 76,215 genomes = 807,162 individuals, aligned to GRCh38, including 416,555 UK Biobank exomes. No v5 as of Aug 2026. Cite the point release — constraint metrics moved in v4.1.1 without the cohort changing. | B | gnomAD news index — release list fetched 2026-08-13; v4.0 announcement for cohort composition | |
No version number — cite the release date. NCBI ships a full weekly /XML plus a monthly archived release named by date: latest monthly ClinVarVCVRelease_2026-08 (posted 2026-08-06), latest weekly VCF clinvar_20260808 (posted 2026-08-10). "The current ClinVar" is not a citable object; a classification can change between two consecutive weeks. | A | ClinVar FTP release listing · fetched 2026-08-13 | |
| 1000 Genomes | Original final release 2,504 unrelated individuals, 26 populations, low-. Expanded high-coverage (30×) release: 3,202 samples including 602 complete trios, NovaSeq 6000, called against GRCh38. | B | 1000 Genomes / NYGC |
| HPRC | Release 2 (May 2025) — 200+ individuals, 460 , ~5× expansion over Release 1. Captures >99% of common variation seen in All of Us v8. Release 1 was 47 individuals / 94 haplotypes. | B | HPRC Data Release 2 |
This corrected a stale assumption. Writing Chapter 45 from memory would have described the 2023 Release 1 draft pangenome as current. It is two years and a fivefold expansion out of date.
Sequencing platforms
Tier C throughout — vendor specifications move fast and marketing figures are best-case. Chapter 40 must give ranges, state the date, and tell the reader to check current specs.
| Platform | Read length | Accuracy | Notes |
|---|---|---|---|
| Illumina NovaSeq X / X Plus | 2×150 bp typical (2×300 available) | ~Q30+, ~0.1% error | 25B flow cell ≈ 8 Tb per flow cell |
| PacBio Revio (HiFi / CCS) | ~15–25 kb | >99.9% consensus (HiFi) | ~100–120 Gb per SMRT Cell in ~24 h at 15–20 kb inserts; ~70–100 Gb at 10–15 kb; ~35–70 Gb at 5–10 kb; 30 h runs at 20–25 kb |
| Oxford Nanopore R10.4.1 / kit V14 | 10s of kb routine; ultra-long >100 kb achievable | simplex ~99.75% (Q26) on current high-accuracy models, against a vendor record of Q28 (99.8%); duplex ~Q30 (>99.9%) | Longest reads. The accuracy gain is in the basecaller, not the chemistry — same pore and kit designation, Q20 → Q26. The duplex figure has no current vendor page behind it: treat as unpinned |
| Roche AXELIOS 1 (SBX) | ~400–600 bp in short-read (simplex) mode; up to ~1,500 bp under favourable sample and library prep | not yet independently benchmarked | Launched 29 June 2026, research-use-only. Sequencing-by-expansion: DNA converted to "Xpandomers" read on a CMOS nanopore sensor. Same-day whole genomes claimed. Roche's own pages are not self-consistent on read length; simplex and duplex modes differ |
Per-row sources, each re-fetched 2026-08-13. Tier C rows rot fastest, so they carry their own URL and date rather than a single date for the section:
| Row | Source | Fetched |
|---|---|---|
| Illumina NovaSeq X / X Plus | NovaSeq X Plus specifications; roadmap from the 23 Feb 2026 release | 2026-08-13 |
| PacBio Revio | pacb.com/revio | 2026-08-13 |
| Oxford Nanopore | nanoporetech.com/platform/accuracy; Q28 record from the 7 Dec 2023 release | 2026-08-13 |
| Roche AXELIOS 1 / SBX | SBX technology overview (400–600 bp); launch release, 29 Jun 2026 (~1,500 bp) | 2026-08-13 |
The Illumina row is deliberately conservative, not stale. Illumina's current spec page gives the 25B flow cell as ~8–10.5 Tb at 2×150; "≈ 8 Tb" sits at the bottom of the vendor's own published range, which is the right way to quote a best-case marketing figure. A February 2026 roadmap announces 25B→35B and 10B→14B flow cells over an 18-month rollout; do not write those as current specifications until a shipped datasheet says so.
This was a genuine knowledge gap. The Roche AXELIOS 1 / SBX platform launched six weeks before this curriculum was written. A chapter on sequencing technology written from memory would have presented a three-horse race (Illumina / PacBio / ONT) and missed a new entrant with a fundamentally different chemistry. Chapter 40 covers it — while being clear that independent benchmarks do not yet exist.
Single-cell droplet platform — the multiplet rate
Tier C · 10x Genomics, An introduction to GEM-X technology, 11 March 2024 · Chromium technology page · both fetched 2026-08-13
| Quantity | Value |
|---|---|
| Multiplet rate, current chemistry (GEM-X) | ~0.4% per 1,000 cells recovered |
| Multiplet rate, preceding chemistry (Next GEM) | ~0.8% per 1,000 recovered — GEM-X is quoted as a "2-fold reduction" |
| Maximum cells per channel | up to 20,000 |
| Median cell recovery, 3′ v4 | ~75% (was ~60% on Next GEM v3.1) |
This is the single most copy-pasted stale number in single-cell methods sections. The rate is linear in cells recovered, so it multiplies straight through into a doublet budget: at 0.4% a 10,000-cell run is ~4% doublets, at the old 0.8–1% it was 8–10%. A protocol inherited from a 2023 paper overstates the doublet burden by ~2×. Chapter 48 uses 0.4% in both §3 and the Ch 48 worked example, and states the previous figure so the reader can spot the substitution in someone else's methods.
Clinical variant interpretation
Tier B · ClinGen SVI
- The operative published standard remains Richards et al. 2015 (ACMG/AMP), as refined by ClinGen Sequence Variant Interpretation working-group recommendations and by gene- and disease-specific Variant Curation Expert Panel specifications.
- ACMG v4 is in draft, previewed at the ACMG 2025 Clinical Genomics Meeting. It restructures and consolidates the evidence codes to be more concept-driven, while leaving the foundational framework intact.
- As of July 2025 ClinGen directs users to its "Variant Classification Guidance" page rather than to a single static document.
Chapter 55 must teach the 2015 framework as the working standard while flagging v4 as imminent. Teaching v4 as current would be wrong; teaching 2015 as unchallenged would be dated. This nuance is exactly the sort of thing a textbook written from memory gets wrong.
ClinGen Cardiomyopathy VCEP — MYH7 specification
Tier A · ClinGen Criteria Specification Registry, record GN002 · JSON fetched 2026-08-13
Record GN002, "ClinGen Cardiomyopathy Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for MYH7 Version 2.0", state Released, approved 2024-04-22. Version 1.0 is Kelly et al. 2018 (PMID 29300372) and is superseded — do not quote its thresholds.
| Criterion | Specification for MYH7 |
|---|---|
| BA1 | Filtering ≥ 0.001 (0.1%) in , popmax subpopulation |
| BS1 | Filtering allele frequency ≥ 0.0001 (0.01%) in gnomAD, popmax subpopulation |
| PM2_Supporting | ≤ 0.00004 in the popmax subpopulation, using the upper bound of the 95% CI (gnomAD displays the FAF, which is the lower bound, so this must be computed) |
| PM1 | in 167–931 (ENST00000355349 / NM_000257.4). "Rule should NOT be combined with PM5" — same-codon pathogenic variants defined the cluster, so combining double-counts |
| PM5 | "PM5 should not be combined with PM1." Where both apply at Moderate, prefer PM5 as variant-specific |
| PP2 | Not applicable for MYH7; the regional enrichment it would capture is already in PM1 |
| PP3 | Approved at Supporting only — Moderate, Strong and Very Strong are all marked not applicable. REVEL ≥ 0.70. Meta-predictors preferred; individual algorithms are not independent criteria |
| PS2 | "For most cardiomyopathies, it is recommended to default to consistency: 'Phenotype consistent with gene but not highly specific'" — which on the SVI de novo point scale is 1 point (Moderate) for confirmed parentage. Shifting up or down requires stated clinical judgement |
This one changed the answer to Chapter 55's flagship worked example. The chapter had applied the general ClinGen REVEL calibration (PP3_Moderate at 0.89) inside a case built on MYH7, while obeying the same panel's PM1 and PP2 rules four lines earlier. The corrected worked example applies the specification to both PP3 (down to Supporting) and PS2 (up to Moderate); the two changes cancel at 6 points, and the standing lesson is that consistency about which rulebook you are in matters more than either individual call.
Hypertrophic cardiomyopathy — gene contributions
Tier A · Sedaghat-Hamedani et al., Clin Res Cardiol 2018;107(1):30–41, PMID 28840316 · abstract fetched 2026-08-13
| Gene | Share of HCM cases |
|---|---|
| MYBPC3 | 20% — the largest single-gene contributor |
| MYH7 | 14% |
| TNNT2, TNNI3 | 2% each |
Meta-analysis of 51 studies, 7,675 HCM patients. The ClinGen MYH7 specification uses a still lower gene contribution (10.6%, from Kelly et al. 2018).
MYH7 is not the largest contributor and its g is not 0.30. Chapter 55's worked example used g ≈ 0.30 and got AF_max = 1.2 × 10⁻⁵; at g = 0.14 it is 5.6 × 10⁻⁶, about 9 in 's ~1.6 million. Whiffin et al. 2017 build the same example on MYBPC3.
GWAS ancestry representation
| Quantity | Value | Tier | Source |
|---|---|---|---|
| European-ancestry share of participants | 88.25% (discovery stage) | A | GWAS Diversity Monitor, fetched 2026-08-13, page timestamp 2026-08-07 |
| African | 0.27% | A | as above |
| African American or Afro-Caribbean | 2.77% | A | as above |
| Asian | 6.09% · Hispanic/Latin American 1.28% · Other/mixed 1.34% | A | as above |
| World-population share of European ancestry | ~16% | A | Martin et al. 2019, Nat Genet, PMC6563838: "~79% of all GWAS participants are of European descent despite making up only 16% of the global population" |
Mind the denominator. 16% is the world share of people of European ancestry, which includes the European-descended populations of the Americas and Oceania. Europe's resident population is ~9%. Chapter 58 used 9% against an ancestry numerator, which nearly doubled the apparent over-representation ratio (5.4× → 9.7×). This is a Tier C-behaving row: the monitor moves, so re-fetch and re-date rather than copying.
Long-range familial search — Erlich et al. 2018
Tier A · Erlich, Shor, Pe'er & Carmi, Science 2018, PMC7549546 · fetched 2026-08-13
- Dataset analysed: 1.28 million individuals tested with a DTC provider.
- "nearly 60% of long-range familial searches return a relative with IBD segments with a total length of 100 cM or more" — this is the hit rate for that 1.28M database, roughly 0.9% of the relevant population.
- "a genetic database needs to cover only 2% of the target population to provide a third-cousin match to nearly any person", and at ~3 million US individuals of European descent (2%), "more than 99% of the people of this ethnicity would have at least a single third-cousin match."
The 60% and the 2% are different results and must never be fused. Writing "~60% at 2% coverage" is a fabrication, and Chapter 58 had additionally back-solved its constant N ≈ 45 from that non-existent datum. No single N fits both published endpoints — 60% at 0.9% coverage needs N ≈ 107, >99% at 2% needs N ≈ 228 — so the independence model
P = 1 − (1 − c)^Nmust be presented as a shape argument with an effective, conservative N, never as a fitted prediction.
Applied genomics — dated events and figures
| Quantity | Value | Tier | Source |
|---|---|---|---|
| UK Generation Study | 200+ conditions, more than 500 genes; 97 genes / 48 conditions added April 2026; about 1 in 100 babies expected to be suspected of a condition (not diagnosed) | A | Genomics England — choosing conditions, fetched 2026-08-13. Supersedes the pre-April-2026 figures 462 genes / 208 conditions / 1 in 200 |
| Genome vs exome diagnostic yield | Within-cohort pooled 30.6% GS vs 23.2% ES, from N = 3 studies; OR 1.7, 95% CI 0.94–2.92, P = .13 — not significant. Three authors are Illumina employees/stockholders | A | Pandey et al., Genet Med 2025;27(6):101398, PMID 40022598, abstract fetched 2026-08-13 |
| EU New Genomic Techniques regulation | European Parliament gave final approval 17 June 2026. Two categories: category 1 (equivalent to conventional breeding) follows a verification route outside the full GMO regime; category 2 stays inside it. Enters into force 20 days after OJ publication, applies two years later | B | Renew Europe, 2026-06-17; Rothamsted, 2026-06-29; Appleyard Lees · fetched 2026-08-13 |
| DOJ interim policy | Approved 09.02.2019, effective 11.01.2019 (2 September and 1 November 2019), per the policy document's own page footer; publicly announced 24 September 2019 | A | DOJ Interim Policy PDF, fetched 2026-08-13 |
| Beacon re-identification cost | 250 queries against a 65-individual beacon; ~5,000 queries against a 1,000-individual beacon. Cost scales with beacon size | A | Shringarpure & Bustamante, AJHG 2015;97(5):631–46, PMID 26522470, abstract fetched 2026-08-13 |
| GEDmatch opt-in | ~185,000 profiles opted back in by late 2019 after the May 2019 switch to opt-out; new users choose at registration with opt-in pre-selected, and 83% stay opted in | B | Guerrini et al., "Four misconceptions about investigative genetic genealogy", PMC8043143, fetched 2026-08-13 |
| Nagoya Protocol scope | Does not cover human genetic material. Genetic resources are "any plant, animal, microbial or material of other origin" | B | UK BRCN guidance, fetched 2026-08-13 |
| Utah Genetic Information Privacy Act | S.B. 227, governor-signed 17 March 2021, effective 5 May 2021 — the DTC genetic-privacy wave began in 2021, not 2025–26 | A | le.utah.gov SB0227 (2021), fetched 2026-08-13 |
| PCSK9 | Gene→hypercholesterolaemia link established 2003 via gain-of-function ADH families (Abifadel et al., Nat Genet, PMID 12730697). ARIC: nonsense in 2.6% of Black participants → 28% LDL, 88% CHD reduction; R46L in 3.2% of white participants → 15% LDL, 47% CHD reduction, HR 0.50 (95% CI 0.32–0.79), P = 0.003 | A | Cohen et al., NEJM 2006;354:1264–72, PMID 16554528, abstract fetched 2026-08-13 |
| He Jiankui | Convicted of illegal medical practice December 2019, three years' imprisonment and ¥3M fine; China's 2020 Criminal Law amendment made implantation of a gene-edited human embryo an offence carrying 3–7 years | B | contemporaneous reporting (Xinhua, Science, STAT), checked 2026-08-13 |
| Genetic adverse selection | Huntington carriers are up to five times as likely as the general population to hold long-term-care insurance; the authors argue modest growth in genetic information could threaten that market's viability | B | Oster, Shoulson, Quaid & Dorsey, NBER w15326 (published J Public Econ 2010), fetched 2026-08-13 |
Still unverified — do not harden. The 85–90% concern / ~40% discrimination figures for people at risk of Huntington disease (Ch 58 §3) have no located source. RUSP condition count (Ch 57 §4) and the DPYD testing-mandate row (Ch 57 §5) were not re-checked; HRSA returns 403. The FDA/PIC PRRS pig approval (Ch 57 §7) is unconfirmed. The EU NGT row above is Tier B pending the Official Journal text — sources disagree on the vote tally, so no tally is quoted in the chapter.
Huntington disease — HTT CAG allele classes
Source: GeneReviews, Huntington Disease (NBK1305) · fetched 2026-08-25 · Tier A
| Quantity | Value |
|---|---|
| Normal | ≤26 CAG |
| 27–35 CAG | |
| Reduced- HD-causing allele | 36–39 CAG |
| Full-penetrance HD-causing allele | ≥40 CAG |
| Prevalence, European ancestry | 9.71:100,000 (up to 17:100,000 with multi-source ascertainment) |
| Prevalence, East Asian and African populations | 0.1–2:100,000 |
| Frequency of ≥36 CAG alleles, European ancestry | as many as 1:400 |
| Age-at-onset variance attributed to CAG length | up to 70% |
| Heritable share of the residual variability | 10%–20% |
Unit warning: all values are repeat units, not base pairs. A 40-repeat allele is 120 bp of CAG tract. Teaching note: of a disease-causing allele (~1:400) exceeds disease prevalence (~1:10,000) by about 25-fold. Nearly the whole gap is 36–39-repeat alleles that never declare themselves.
Repeat-expansion disorders — repeat, location and thresholds
Sources: GeneReviews chapters (Tier A, each fetched 2026-08-25) and the STRipy STR database (Tier B, fetched 2026-08-25)
| Quantity | Value | Tier | Source |
|---|---|---|---|
| HTT repeat motif and location | CAG, coding exon 1 | A | GeneReviews NBK1305 |
| AR (SBMA) normal / reduced- / pathogenic | ≤34 / 36–37 / ≥38 | A | GeneReviews NBK1333 |
| ATN1 (DRPLA) normal / intermediate / pathogenic | 6–35 / 35–47 / 48–93 | A | GeneReviews NBK1491 |
| ATXN1 (SCA1) full penetrance | 39–44 CAG uninterrupted by CAT | A | GeneReviews NBK1184 |
| ATXN2 (SCA2) normal / at-risk / pathogenic | ≤31 / 33–34 / ≥35 | A | GeneReviews NBK1275 |
| ATXN3 (SCA3) normal / intermediate / pathogenic | 12–44 / 45–59 / ~60–87 | A | GeneReviews NBK1196 |
| CACNA1A (SCA6) normal / pathogenic | ≤18 / 20–33 | A | GeneReviews NBK1140 |
| ATXN7 (SCA7) normal / mutable / reduced-penetrance / full | 7–27 / 28–33 / 34–36 / 37–460 | A | GeneReviews NBK1256 |
| TBP (SCA17) normal / reduced-penetrance / full | 25–40 / 41–48 / ≥49 | B | GeneReviews NBK1438 (secondary read) |
| DMPK (DM1) motif and location | CTG, 3′ UTR | A | GeneReviews NBK1165 |
| DMPK normal / / pathogenic / congenital | 5–34 / 35–49 / >50 / usually >1,000 | A | GeneReviews NBK1165 |
| CNBP (DM2) motif, location, pathogenic range | CCTG, 1, ~75–11,000 (mean ~5,000) | A | GeneReviews NBK1466 |
| FMR1 normal / grey zone / premutation / full | ~5–44 / 45–54 / 55–200 / >200 (CGG, 5′ UTR) | A | GeneReviews NBK1384 |
| FXN (FRDA) motif, location, normal / pathogenic | GAA, intron 1, 5–33 / 66–~1,300 | A | GeneReviews NBK1281 |
| C9orf72 normal / uncertain / pathogenic | 2–24 / 25–60 / 61 – >4,000 (GGGGCC, intron 1) | A | GeneReviews NBK268647 |
| ATXN10 (SCA10) motif, location, normal / full | ATTCT, intron 9, 10–32 / 800–4,500 | A | GeneReviews NBK1175 |
| ATXN8OS/ATXN8 (SCA8) normal / typical pathogenic | 15–50 / 54–250 combined (CTA·TAG)n(CTG·CAG)n | A | GeneReviews NBK1268 |
| RFC1 (CANVAS) pathogenic motif and size | biallelic (AAGGG)₄₀₀–₂₀₀₀₊, intron 2 | A | GeneReviews NBK564656 |
| DAB1 (SCA37) pathogenic | (ATTTC)₃₁–₇₅ inserted inside an (ATTTT)n | A | Seixas et al., AJHG 201730242-2) |
| FGF14 (SCA27B) pathogenic threshold | ≥250 GAA (250–300 reduced penetrance; ≥300 full) | B | Pellerin et al., NEJM 2023 |
| ZFHX3 (SCA4) motif and product | GGC → polyglycine, coding; pathogenic ≥42 | B | Nat Genet 2024;56:1080–1089 |
Assembly note: none of these thresholds are coordinates, so no assembly applies — but any genomic coordinate for a repeat locus must name GRCh38 or and its 0-/1-based convention, because STR callers differ on both. Unit warning: STRipy and GeneReviews disagree at ATXN7, ATXN3, C9orf72, ATN1 and AR. Where they disagree, the GeneReviews value is the one recorded here.
SCA12 — PPP2R2B repeat and thresholds
Source: Srivastava et al., Brain 2017;140(1):27–36 and STRipy · fetched 2026-08-25 · Tier C — contested, give as a range
| Quantity | Value | Tier | Source |
|---|---|---|---|
| Gene and locus | , 5q32 | B | Holmes et al. 1999; secondary reads |
| Repeat motif and position | CAG, ~133 nt upstream of the reported start site (5′ region / probable ) | B | secondary reads of the PPP2R2B literature |
| Control repeat range | 4–31 (Srivastava cohort); 4–32 quoted elsewhere | A | Srivastava et al. 2017 |
| Classical pathogenic threshold | ≥51 | B | STRipy; long-standing convention |
| GeneReviews chapter | NBK1202 — last updated 2011-11-17, retired 2018-12-13 ("RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY"). While current it gave ≥51 diagnostic in the right clinical context, normal 4–32, and stated the threshold itself was "not clear", with 40–62 seen with variable, late or absent onset | B | GeneReviews NBK1202 · fetched 2026-08-25 |
| Revised lower threshold argued | ≥43 — "the shortest pathogenic length for the SCA12 " | A | Srivastava et al. 2017 (18 patients, 16 unrelated families, CAG 43–50) |
| Repeat length vs age at onset | Pearson r = −0.65, P < 10⁻⁴, n = 124 unrelated patients | A | Srivastava et al. 2017 |
| Discovery | Holmes et al., Nat Genet 1999;23(4):391–392 | B | citation verified by search; paper not fetched |
| Nuclear CAG RNA foci in SCA12 patient iPSC-derived neural stem cells, absent from controls; pull-down identifies 13 proteins binding the expanded repeat exclusively | demonstrated in cells; no fraction-of-cells figure and no length threshold reported | A | Kumar et al. 2024, iScience 27(5):109768, PMID 38711441 |
| at the SCA12 locus | demonstrated in cells and iPSC-derived neurons, in multiple frames — polyglutamine and polyserine from the sense strand (Delhi group), polyalanine from the antisense PPP2R2B-AS1 ORF (Hopkins group), polyleucine and polycysteine absent. Frames not reconciled between labs; no RAN product has been demonstrated in SCA12 human brain | A | Kumar et al. 2024, iScience; Zhou et al. 2023, Mov Disord 38(12):2230–2240 |
| Bidirectional transcription at PPP2R2B: antisense PPP2R2B-AS1 carries a CUG repeat, forms CUG RNA foci in SK-N-MC cells and induces apoptosis | demonstrated in cells; expanded transcripts reliably detected only in iPSCs and mouse models, not in post-mortem brain | A | Zhou et al. 2023, Mov Disord 38(12):2230–2240 |
Teaching note: the mechanism is not settled either. The long-standing working model is cis-regulatory mis-setting of PPP2R2B expression, but RNA foci and RAN translation are now reported at this locus, and Kumar 2024 finds most PPP2R2B isoforms down in patient-derived mature neurons — which contradicts the up-regulation model the field has run on since 2010. Do not write "no toxic RNA, no translated product" for SCA12.
Teaching note: the SCA12 threshold is not settled. Tell the reader the range (43–51), name the paper that moved it, and say the field has not converged as of August 2026. A course that reports "51" as a fact is teaching a convention as though it were a measurement.
Human brain — neuron numbers
Source: Azevedo et al. 2009, J Comp Neurol 513(5):532–41 · fetched 2026-08-25 · Tier A
| Quantity | Value |
|---|---|
| Neurons, whole adult human brain | ≈ 86 billion |
| Neurons, | ≈ 69 billion (≈ 80% of all brain neurons) |
| Mass, cerebellum | ≈ 154 g (≈ 10% of brain mass) |
| Neurons, cerebral cortex incl. white matter | ≈ 16 billion (≈ 19%) |
| Mass, cerebral cortex incl. white matter | ≈ 1,233 g |
| Non-neuronal cells, whole brain | ≈ 85 billion (glia : neuron ≈ 1 : 1) |
Teaching note. The 10:1 glia-to-neuron ratio in older textbooks is wrong; this study is where the correction comes from. Note also that the cerebellum holds four-fifths of the brain's neurons in one-tenth of its mass — "cerebellar disease" is not a disease of a small structure.
Human cerebellum — cell counts (contested)
Source: Nairn et al. 1989, J Comp Neurol 290(4):527–32 · Andersen, Korbo & Pakkenberg 1992, J Comp Neurol 326(4):549–60 · Azevedo et al. 2009 · fetched 2026-08-25 · Tier C
| Quantity | Value | Tier | Source |
|---|---|---|---|
| , whole | 15.4 × 10⁶ (CV 19%, n = 12) | C | Nairn 1989, fractionator |
| Purkinje cells, whole cerebellum | 30.5 × 10⁶ (CV 0.13, n = 5) | C | Andersen 1992, optical disector |
| Granule cells, whole cerebellum | 101 × 10⁹ (CV 0.13) | C | Andersen 1992 |
| All cerebellar neurons | ≈ 69 × 10⁹ | A | Azevedo 2009, isotropic fractionator |
| Neurons, dentate nucleus | 5.01 × 10⁶ (CV 0.28) | A | Andersen 1992 |
| Cerebellar cortical surface area | 1,160 cm² (CV 0.29) | A | Andersen 1992 |
This is a genuine, unresolved disagreement. Purkinje-cell estimates differ two-fold and granule-cell estimates conflict with the whole-cerebellum neuron count. Quote as 15–30 million Purkinje cells and ~70–100 billion granule cells, and tell the reader the spread is a fact about counting methods (nucleoli vs nuclei vs homogenate), not about people.
Human Purkinje cell — morphology
Source: Masoli et al. 2024, Commun Biol 7:5 · fetched 2026-08-25 · Tier A
| Quantity | Value |
|---|---|
| Total dendritic length, human PC | 20,167 ± 15,249 µm |
| Total dendritic length, mouse PC | 2,783 ± 671 µm |
| Human : mouse dendritic length | 7.24× |
| Dendritic spines, human PC | 38,417 ± 29,210 (max 97,853) |
| Dendritic spines, mouse PC | 5,064 ± 1,342 |
| Spine density, both species | ≈ 2 spines/µm |
| Human PCs with 2–3 primary dendritic trunks | 80% (mouse 10.5%) |
| Dendritic complexity index, human : mouse | 27× |
Tier C caveat. A 2025 review from the same group quotes ≈ 35,000 (rodent) and ≈ 360,000 (human) spines and human dendritic lengths of 30,000–63,645 µm (Masoli et al. 2025, Front Physiol 16:1671271). Reconstruction method drives the difference. Write "tens of thousands to a few hundred thousand parallel-fibre inputs per human ".
Purkinje cell — firing
Source: Arancillo et al. 2015, J Neurophysiol 113(2):578–91 · fetched 2026-08-25 · Tier B
| Quantity | Value |
|---|---|
| Simple-spike rate, spontaneous in vivo | mean ≈ 40 Hz, range 0–200 Hz |
| Intrinsic pacemaker range, regular firing | 30–150 Hz |
| Complex-spike (climbing-fibre) rate | ≈ 0.5–1 Hz |
Teaching note. are intrinsic pacemakers — they fire with all synaptic input blocked (Raman & Bean 1999, J Neurosci 19(5):1663–74). This is the load-bearing fact behind the firing-energetics account of their .
Brain energetics
Source: Attwell & Laughlin 2001, J Cereb Blood Flow Metab 21(10):1133–45 · fetched 2026-08-25 · Tier A (model) / B (body-share figures)
| Quantity | Value | Tier |
|---|---|---|
| Brain share of body mass | ≈ 2% | B |
| Brain share of body oxygen consumption | ≈ 20% | B |
| Brain share of body glucose consumption | ≈ 25% | B |
| Grey-matter signalling budget: action potentials | 47% | A |
| … postsynaptic effects of glutamate | 34% | A |
| … resting potential | 13% | A |
| … glutamate recycling | 3% | A |
Unit and scope warning. The 47/34/13/3 split is a calculated budget for rodent grey matter, not a measurement of human , and later work revised the action-potential share downward (mammalian spikes are more Na⁺-efficient than assumed) while raising non-signalling costs (Engl & Attwell 2015, J Physiol 593(16):3417–29). Use it for the qualitative claim only.
SARA — Scale for the Assessment and Rating of Ataxia
Source: Schmitz-Hübsch et al. 2006, Neurology 66(11):1717–20 · item structure from Shirley Ryan AbilityLab RehabMeasures · fetched 2026-08-25 · Tier A / B
| Quantity | Value | Tier |
|---|---|---|
| Items | 8 | B |
| Total score range | 0 (no ) – 40 (most severe) | B |
| Item ranges | Gait 0–8 · Stance 0–6 · Sitting 0–4 · Speech 0–6 · Finger chase 0–4 · Nose–finger 0–4 · Fast alternating movements 0–4 · Heel–shin 0–4 | B |
| Validation cohorts | 167 and 119 SCA patients | A |
| Interrater reliability | ICC 0.98 | A |
| Test–retest reliability | ICC 0.90 | A |
| Internal consistency | Cronbach's α 0.94 | A |
| Administration time | 14.2 ± 7.5 min (range 5–40) | A |
| Correlation, Barthel Index | r = −0.80 | A |
| Correlation, UHDRS-IV | r = −0.89 | A |
| Correlation, disease duration | r = 0.34 | A |
| Minimal clinically important difference | not established | C |
Two warnings. (1) Gait (8) plus stance (6) supply 35% of the maximum score, so SARA is weighted toward axial function; limb-predominant change moves it little. (2) High reliability with no established MCID means a reported point-change has no independently anchored clinical meaning. Reliability is not interpretability.
Human kinases and phosphatases
Source: Manning et al. 2002, Science 298(5600):1912–34 · Shi 2009, Cell 139(3):468–84 · Olsen et al. 2006, Cell 127(3):635–48 · fetched 2026-08-25 · Tier A / B
| Quantity | Value | Tier | Source |
|---|---|---|---|
| Protein kinase genes, human | 518 (≈ 1.7% of genes) | A | Manning 2002 |
| … Ser/Thr kinases | 428 | B | Shi 2009 |
| … Tyr kinases | 90 | B | Shi 2009 |
| Protein tyrosine genes | 107 | B | Alonso 2004 / Shi 2009 |
| Ser/Thr phosphatase catalytic subunit genes | ≈ 30 (PPP + PPM) | B | Shi 2009 |
| Phosphosite distribution Ser : Thr : Tyr | ≈ 86 : 12 : 2 | B | Olsen 2006 |
The asymmetry is the point. 428 Ser/Thr kinases against ~30 Ser/Thr phosphatase catalytic subunits means phosphatase specificity cannot live in the catalytic subunit. It is built combinatorially by targeting subunits — which is what 's B subunits are.
PP2A — holoenzyme architecture
Source: Sandal et al. 2021, J Cell Sci 134(13):jcs248187 · Haanen, O'Connor & Narla 2022, J Biol Chem 298(12):102656 · Xu et al. 2006, Cell 127(6):1239–51 · fetched 2026-08-25 · Tier A / B / C
| Quantity | Value | Tier | Source |
|---|---|---|---|
| Composition | heterotrimer: scaffold A + catalytic C + regulatory B | A | Xu 2006 |
| A-subunit genes | PPP2R1A, PPP2R1B | A | Sandal 2021 |
| A-subunit structure | 15 HEAT repeats, L-shaped superhelix | A | Xu 2006 |
| C-subunit genes | PPP2CA, PPP2CB | A | Sandal 2021 |
| B families | B/B55 (PPP2R2A–D) · B′/B56 (PPP2R5A–E) · B″/PR72 (PPP2R3A–C) · B‴/striatin (STRN, STRN3, STRN4) | A | Sandal 2021; Haanen 2022 |
| B-subunit genes / variants | 15 genes, ≥ 26 transcript and splice variants | B | Haanen 2022 |
| B55 fold | seven-bladed WD40 β-propeller with acidic top groove | A | Xu 2006 |
| Distinct holoenzymes formable | ≈ 60–100 | C | "over 60" Haanen 2022; "nearly 100" Sandal 2021 |
| share of cellular Ser/Thr dephosphorylation | ≥ 50% in most cell types | B | Sandal 2021 |
| PP2A as fraction of total cellular protein | up to ~1% in some tissues | B | reviewed in Shi 2009 |
Range honesty. The holoenzyme count is a combinatorial upper bound from subunit arithmetic, not a census. Not every combination assembles, and observed abundances differ by orders of magnitude (Bβ2 holoenzymes are ~10-fold rarer than Bβ1; Dagda 2003).
PPP2R2B — gene and isoforms
Source: GTEx reference API (GRCh38/hg38) · OMIM #604326 · Dagda et al. 2003, J Biol Chem 278(27):24976–85 · Strack et al. 1998, J Comp Neurol 392(4):515–27 · fetched 2026-08-25 · Tier A
| Quantity | Value |
|---|---|
| Product | B55β / Bβ / PR55β, a |
| Location | 5q32; chr5:146,581,146–147,084,784 (GRCh38), minus strand (GENCODE model via GTEx; the NCBI RefSeq span differs — see — locus anatomy below) |
| Entrez / Ensembl | 5521 / ENSG00000156475 |
| SCA12 CAG tract position | 133 nt upstream of the reported start site — 5′ regulatory, not coding |
| Isoforms | Bβ1 (cytosolic) and Bβ2 (outer mitochondrial membrane), differing only in the N-terminal tail |
| Effect of the Bβ2 N-terminus on catalysis | none — pure targeting signal; the tail alone targets GFP to mitochondria |
| Bβ2 : Bβ1 holoenzyme abundance | Bβ2 ≈ 10-fold less abundant |
| Bβ2 N-terminal gating residues | Ser20/21/22; phosphorylation neutralises the import signal's +3 charge and holds Bβ2 cytosolic |
| Tissue restriction of Bβ protein | detectable only in brain (unlike A, Bα, C) |
| Bβ2 regional bias | predominantly forebrain |
The structural point. The SCA12 repeat is not in the ORF and makes no polyglutamine tract. SCA12 is a regulatory-dosage disease; the repeat acts as a cis element that up-regulates (Lin et al. 2010, Hum Genet 128(2):205–12).
PPP2R2B — expression (corrects a common claim)
Source: GTEx v8 median gene TPM, API ENSG00000156475.18 · Human Protein Atlas · fetched 2026-08-25 · Tier A / B
| Quantity | Value | Tier |
|---|---|---|
| Highest tissue, GTEx v8 | Brain — Frontal Cortex (BA9), 29.90 | A |
| Brain — Cortex | 24.66 TPM | A |
| Brain — | 10.16 TPM | A |
| Brain — Cerebellar Hemisphere | 8.76 TPM | A |
| Median across 41 non-brain tissues | 0.50 TPM | A |
| Cells — Cultured fibroblasts | 0.011 TPM | A |
| HPA tissue specificity | group enriched (brain, retina, testis) | B |
| HPA brain-region specificity | low region specificity, detected in all regions | B |
Correction. is strongly brain-enriched but not cerebellum-enriched: cerebellum ranks below every cortical and basal-ganglia region GTEx samples, and frontal cortex is ~3× higher. The cerebellar of is therefore not explained by where the gene is transcribed — it is an instance of selective neuronal vulnerability, not a solution to it.
Unknown, stated as unknown. Bulk cerebellar is dominated by granule cells, which outnumber by ~10³–10⁴. These data cannot rule out Purkinje-cell-specific enrichment; they rule out cerebellum-level enrichment. No published single-nucleus analysis of PPP2R2B by cerebellar cell type was found.
PP2A — tau phosphatase activity
Source: Liu et al. 2005, Eur J Neurosci 22(8):1942–50 · fetched 2026-08-25 · Tier A
| Quantity | Value |
|---|---|
| share of total tau activity, human brain | ≈ 71% |
| PP1 | ≈ 11% |
| PP5 | ≈ 10% |
| PP2B (calcineurin) | ≈ 7% |
| Km, tau dephosphorylation by PP1 / PP2A / PP5 | 8–12 µM (≈ intraneuronal tau concentration) |
| Km, PP2B | 5-fold higher |
| In Alzheimer's disease brain | total and PP2A/PP5 tau-phosphatase activity decreased; PP2B increased |
Why the Km matters. With Km near the physiological substrate concentration, PP2A's flux tracks its abundance — the enzyme is neither saturated nor idle. That is the enzymological reason a dosage change in a PP2A subunit is not automatically buffered.
PP2A — DRP1 and mitochondrial fission
Source: Dickey & Strack 2011, J Neurosci 31(44):15716–26 · Merrill, Slupe & Strack 2013, FEBS J 280(2):662–73 · fetched 2026-08-25 · Tier A
| Quantity | Value |
|---|---|
| DRP1 inhibitory phosphosite | Ser637 (human) = Ser656 (rat) |
| Kinase (inhibits fission) | PKA, anchored by AKAP1 at the outer mitochondrial membrane |
| (promote fission) | /Bβ2 and calcineurin (PP2B) |
| Consequence of PP2A/Bβ2 action in neurons | mitochondria fragment and depolarise, are depleted from dendrites; dendritic outgrowth stunted, synapse number rises |
| Bβ2 targeting mechanism | cryptic mitochondrial import signal + unfolding-resistant arrest domain, stalling the protein in the outer membrane |
PP2A — regulation and inhibitors
Source: Haanen et al. 2022, J Biol Chem 298(12):102656 · Tanimukai et al. 2005, Am J Pathol 166(6):1761–71 · Junttila et al. 2007, Cell 130(1):51–62 · fetched 2026-08-25 · Tier A / B
| Quantity | Value | Tier |
|---|---|---|
| Methylated residue on -C | Leu309 (C-terminal carboxylate) | B |
| Methyltransferase | LCMT1; methylation permits B55 and B56 binding | B |
| Methylesterase | PME-1; demethylation disfavours B binding and protects free C from proteasomal degradation | B / A |
| Biogenesis chaperones | α4 (IGBP1), PTPA | B |
| Endogenous inhibitors | I₁PP2A (ANP32A), I₂PP2A (SET) — both up-regulated in AD neocortex; I₂PP2A relocates nucleus → cytoplasm and its 39-kDa form is cleaved to ~20 kDa in AD | A |
| Oncogenic inhibitor | CIP2A — blocks PP2A toward c-Myc Ser62, stabilising c-Myc | A |
| Pharmacological inhibitors | okadaic acid, microcystin-LR (active-site binders; co-crystal structures available) | A |
Regulatory framing. PP2A is controlled chiefly by which holoenzyme assembles, not by dialling a catalytic rate. Methylation state, chaperone availability and subunit stoichiometry all act on assembly — which is why a change in the amount of one B subunit is a credible pathogenic mechanism.
PP2A B-subunit dosage — hypothesis, not fact
Source: reasoning from Xu et al. 2006, Sandal et al. 2021, Haanen et al. 2022, Dagda et al. 2003 · assessed 2026-08-25 · Tier C
| Claim | Status |
|---|---|
| Substrate specificity and targeting reside in the B subunit | Established (structural + functional) |
| 15 B-subunit genes compete for cores built from 2 A and 2 C genes | Established (gene counts) |
| Holoenzyme assembly is a methylation- and chaperone-gated binding equilibrium | Established |
| Therefore raising one B subunit displaces others from a limiting A–C core pool | Not demonstrated quantitatively — asserted in reviews, follows from the above, but no primary measurement of the free-core pool or of endogenous B-subunit displacement at disease-relevant dosage was found |
| Bβ2's pro-apoptotic effect requires holoenzyme assembly (assembly-defective mutant is inert) | Established (Dagda 2003) — consistent with, but not proof of, competition |
Write it as a hypothesis with its logic exposed, and name the experiment that would settle it: quantitative interaction proteomics of the A subunit across a dosage series, measuring the full B-subunit occupancy distribution rather than the overexpressed subunit alone.
Somatic instability and mismatch repair in Huntington disease
Sources: GeM-HD Consortium papers and Handsaker et al. 2025 · fetched 2026-08-25
| Quantity | Value | Tier | Source |
|---|---|---|---|
| GeM-HD 2015: 15 locus, effect 1 | hastens onset by 6.1 years | B | GeM-HD, Cell 2015;162(3):516–526 |
| GeM-HD 2015: chromosome 15 locus, effect 2 | delays onset by 1.4 years | B | GeM-HD, Cell 2015;162(3):516–526 |
| GeM-HD 2015: chromosome 8 locus | hastens onset by 1.6 years | B | GeM-HD, Cell 2015;162(3):516–526 |
| GeM-HD 2019: cohort size | 9,064 unique HD subjects of European ancestry | A | GeM-HD, Cell 2019;178(4):887–900 |
| GeM-HD 2019: modifier genes | FAN1 (chr15, top locus), MSH3/DHFR (chr5), PMS1 (chr2), MLH1 (chr3), PMS2 (chr7), LIG1 (chr19), RRM2B/UBR5 (chr8) — all | A | GeM-HD, Cell 2019 |
| GeM-HD 2019: the CAA result | loss of the CAACAG → earlier onset; CAACAG duplication (more glutamines) → later onset. Uninterrupted CAG length, not polyQ length, drives timing | A | GeM-HD, Cell 2019 |
| Somatic threshold in striatal projection neurons | ≈150 CAG; SPNs below it look transcriptionally normal, above it lose identity | B | Handsaker et al., Cell 2025;188(3):623–639.e19 |
| Somatic expansion and onset, human brain | longer somatic expansion in brain associates with earlier onset | A | Swami et al., Hum Mol Genet 2009;18(16):3039–3047 |
| Age-dependent somatic expansion, mechanism | OGG1-initiated "toxic oxidation" cycle in post-mitotic cells | A | Kovtun et al., Nature 2007;447:447–452 |
Do not quote per-locus effect sizes in years from the 2019 paper. Two automated reads of the PMC full text returned mutually inconsistent values for the same table rows, and the PMC table endpoint was CAPTCHA-gated on 2026-08-25. The 2015 figures above are safe; the 2019 per- figures must be read from Table 1 by eye before any chapter uses them.
Interruptions, premutations and reduced penetrance
Sources: GeneReviews chapters · fetched 2026-08-25 · Tier A unless marked
| Quantity | Value | Tier | Source |
|---|---|---|---|
| HD reduced- penetrance (36–38 CAG) | 0.2%–2% across a typical life span | B | GeneReviews NBK1305 |
| SBMA: clinical prevalence vs | ~1:300,000 males clinically, but 1:6,887 males carry a pathogenic expansion | A | GeneReviews NBK1333 |
| FMR1 AGG interruptions | occur about every 9–10 CGG; presence reduces risk of expansion to full for alleles <100 repeats | A | GeneReviews NBK1384 |
| FMR1 grey-zone expansion risk | about 14% of 45–54-repeat alleles expand into the range on maternal transmission | A | GeneReviews NBK1384 |
| FXTAS penetrance in male premutation carriers | 17% (50–59 y), 38% (60–69 y), 47% (70–79 y), 75% (≥80 y) | A | GeneReviews NBK1384 |
| FXTAS penetrance in female premutation carriers >50 y | 16%–20% (vs ~40% in males) | A | GeneReviews NBK1384 |
| ATXN1 CAT interruptions | a 36–44 CAG allele with CAT is normal; without CAT it is mutable or pathogenic | A | GeneReviews NBK1184 |
| ATXN10 ATCCT interruption | associated with higher prevalence of epileptic seizures; interrupted alleles show with paradoxical repeat contraction | A | GeneReviews NBK1175 |
| SCA8 penetrance | reduced penetrance at repeats of all sizes; alleles 71 – >1,300 occur in affected and unaffected people | A | GeneReviews NBK1268 |
| DM2 – | no significant correlation between CCTG size and age of onset or severity; anticipation not confirmed | A | GeneReviews NBK1466 |
| SCA6 anticipation | not observed | A | GeneReviews NBK1140 |
| DRPLA anticipation | offspring onset ~26–29 y earlier than affected fathers, ~14–15 y earlier than affected mothers | A | GeneReviews NBK1491 |
| DM1 transmitted expansion size | paternal median 425 (range 70–2,000); maternal median 200 (range 57–1,400) | A | GeneReviews NBK1165 |
| FRDA onset by GAA1 length | GAA1 <700 → mean onset 18 y; >700 → mean onset 9.7 y; <500 → onset >25 y; <300 → onset >40 y | A | GeneReviews NBK1281 |
| FRDA carrier frequency | 1/60–1/100 | A | GeneReviews NBK1281 |
| C9orf72 share of ALS/FTD | 30–50% familial ALS, 4–10% sporadic ALS, ~25% familial FTD | A | GeneReviews NBK268647 |
| RFC1 share of adult-onset | 14%–22%; 82%–97% of full-CANVAS phenotypes | A | GeneReviews NBK564656 |
| SCA3 share of ataxia families | 20%–50% worldwide; 21%–25% in the US and Canada | A | GeneReviews NBK1196 |
Teaching note: "premutation", "" and "reduced-penetrance allele" are three different things. An intermediate allele is unstable but harmless to its carrier; a premutation (the FMR1 55–200 case) causes a different disease by a mechanism the full mutation cannot use; a reduced-penetrance allele (HD 36–39) is the disease allele in someone who may never manifest.
SCA12 — locus anatomy
Source: STRchive SCA12_PPP2R2B, STRchive-loci.json · fetched 2026-08-25 · Tier A
| Quantity | Value |
|---|---|
| Gene | |
| Cytoband | 5q32 |
| Gene strand | minus |
| Repeat, GRCh38 | chr5:146,878,728–146,878,759 |
| Repeat, GRCh37 | chr5:146,258,291–146,258,322 |
| Repeat, | chr5:147,414,734–147,414,765 |
| Reference copy number | 10.7 |
| Motif, plus/reference strand | GCT (i.e. the tract reads CTG-like on the plus strand) |
| Motif, gene/sense strand | AGC (i.e. the tract reads CAG-like on the mRNA) |
| Region | 5′ UTR |
| Gene span, GRCh38 | chr5:146,580,742–147,081,520 |
| RefSeq transcript variants | 10 |
Unit and strand warning.
(CAG)n,(CTG)n,(AGC)nand(GCT)nin the literature all name the same ~32-bp reference element (30 bp as the ExpansionHunter catalog bounds it, 32 bp as STRchive does). PPP2R2B is on the minus strand, so the disease-relevant CAG reading is on the mRNA and the plus-strand genome browser shows CTG; a trinucleotide repeat has no canonical , so databases differ by a cyclic rotation. Never infer a different locus from a different motif spelling.
SCA12 — allele ranges (sources disagree)
| Quantity | Value | Tier | Source |
|---|---|---|---|
| Normal | 4–32 | B | GeneReviews chapter (retired 2018-12-13), fetched 2026-08-25 |
| Normal alleles | 6–32 | A | STRchive JSON, fetched 2026-08-25 |
| Normal alleles | 4–31 | A | Srivastava et al. 2017, Brain 140(1):27–36 |
| Benign call anchor | 7–28 | A | RCV000005966, NM_181675.3(PPP2R2B):c.27CAG[(7_28)], fetched 2026-08-25 |
| 40–49 | A | STRchive JSON, fetched 2026-08-25 | |
| "Intermediate pathogenic" | 43–50 | A | Srivastava et al. 2017, Brain 140(1):27–36 |
| Pathogenic alleles | 51–78 | A | STRchive JSON; GeneReviews (retired) gives ≥51 as diagnostic |
| Proposed lowered threshold | ≥43 | A | Srivastava et al. 2017, Brain 140(1):27–36 |
| Shortest reported pathogenic allele | 46 | A | Dong, Wu & Wu 2015, Parkinsonism Relat Disord 21(4):398–401 |
| Shortest reported symptomatic alleles | 40 and 42 | A | Ganaraja et al. 2022, Tremor Other Hyperkinet Mov 12:13 |
| Index-family expanded alleles | 66–78 (fully penetrant) | B | GeneReviews SCA12 chapter (retired) |
| Indian founder expanded alleles | 51–69 | A | Bahl et al. 2005, Ann Hum Genet 69(Pt 5):528–534 |
| Non-penetrant / very-late-onset carriers | reported at 45–62 | B | GeneReviews SCA12 chapter (retired) |
| Unaffected carriers within an affected family | CAG-39 | A | Srivastava et al. 2017, Brain 140(1):27–36 |
Teaching note. ≥51 CAG with a compatible is diagnostic and ≤31 is normal — everything from 32 to 50 is contested territory, and the boundary has moved downward twice since 2015 (46, then 43, then symptomatic cases at 40). Report a 44-repeat allele as "in a range where pathogenicity is reported but not established", never as "negative".
SCA12 — epidemiology
| Quantity | Value | Tier | Source |
|---|---|---|---|
| Fraction of Indian referrals (pan-India, ~5,600 patients, 10 yr) | 8.6% (490) | A | Sharma et al. 2022, Adv Genet 3(2):2100078 |
| SCA2 in the same cohort, for comparison | 8.5% (482) | A | Sharma et al. 2022 |
| Fraction of AD ataxia at AIIMS North India | ~16% (20/124) | A | Bahl et al. 2005, Ann Hum Genet 69(Pt 5):528–534 |
| Agarwal ancestry in a 49-patient Indian cohort | 79.6% (10.2% explicitly non-Agarwal) | A | Ganaraja et al. 2022, Tremor 12:13 |
| association with expanded | P = 0.000, 20 families, markers spanning ~137 kb | A | Bahl et al. 2005 |
| Independent origins of the expansion | ≥2 (Indian founder haplotype absent from the American ) | A | Bahl et al. 2005 |
| Yield in a European ataxia | 1 family / 247 index cases | A | Fujigasaki et al. 2001, Ann Neurol 49(1):117–121 |
| expansions in familial essential tremor probands | 1 / 515 (of 6/515 pathogenic STR expansions total) | A | Zhou X et al. 2024, Brain Commun, PMID 38961870 |
| Population prevalence per 100,000 | no published estimate | — | STRchive prevalence: null; absent from GeneReviews and Orphanet |
Teaching note. "Second commonest SCA in India" is the familiar line and comes from a 124-family AIIMS series. The largest series (Sharma 2022, ~5,600 referrals) puts fractionally ahead of SCA2 — 8.6% vs 8.5%, a margin inside the noise. Say "SCA12 and SCA2 are jointly the commonest SCAs in Indian referral cohorts", and never convert a referral fraction into a population prevalence.
SCA12 — clinical phenotype
Source: Ganaraja et al. 2022, Tremor Other Hyperkinet Mov 12:13 (n = 49 from 42 families) · fetched 2026-08-25 · Tier A
| Quantity | Value |
|---|---|
| Tremor at presentation | 95.9% |
| at presentation | 73.5% |
| Head tremor | 55.1% |
| Voice tremor | 42.8% |
| Impaired tandem gait | 89.8% |
| Dysmetria | 75.5% |
| Dysarthria | 57.1% |
| Cognitive dysfunction | 22.4% |
| Psychiatric disturbance | 8.1% |
| Mean age at onset | 46.38 ± 11.7 yr |
| Mean expanded repeat length | 53.26 ± 6.10 |
| Positive family history | 93.8% |
| MRI: cerebellar atrophy only | 34.7% |
| MRI: cerebral atrophy only | 16.3% |
| MRI: both | 34.7% |
| MRI: normal | 6.1% |
| Quantity | Value | Tier | Source |
|---|---|---|---|
| Cognitive impairment (dedicated non-motor study, n=34) | 61.76% | A | Basu et al. 2024, Front Neurol 15:1464149 |
| Psychiatric disorders (n=21) | 67% | A | Choudhury et al. 2018, Mov Disord Clin Pract 5(1):39–46 |
| Tremor as first symptom (n=21) | 90% | A | Choudhury et al. 2018 |
| Mean age at onset (n=21) | 51.33 ± 8.98 yr, range 41–69 | A | Choudhury et al. 2018 |
| Repeat length vs age at onset | r = −0.760, P = 0.0001 | A | Choudhury et al. 2018 |
| Repeat length vs age at onset | no significant correlation | A | Ganaraja et al. 2022 |
| Typical onset window | 26–50 yr; full range 8–62 yr | A | STRchive JSON |
| Index-family onset | "fourth decade", mean 34–38 yr | B | GeneReviews chapter (retired) |
| Life expectancy | believed not shortened; no survival study published | C | National Ataxia Foundation, fetched 2026-08-25 |
Teaching note. The two Indian cohorts disagree about whether repeat length predicts onset age (r = −0.76 vs none) and the index family looks a decade or two younger at onset than any Indian series. Both disagreements are live. Quote a cohort, never a consensus.
Diagnostic warning. 6.1% of a genetically confirmed SCA12 cohort had a normal MRI, and two short-duration patients in a second cohort had no atrophy. Imaging supports the diagnosis; it never excludes it.
SCA12 — anticipation and instability (contested)
| Quantity | Value | Tier | Source |
|---|---|---|---|
| "Insufficient evidence for anticipation" | A | GeneReviews Hereditary Overview, last revised 2026-07-09, fetched 2026-08-25 | |
| Anticipation | "a moderate degree of anticipation has been observed" | B | GeneReviews chapter, retired 2018-12-13 |
| instability | "modestly unstable, length variations of a few triplets among sibship members" | B | GeneReviews SCA12 chapter (retired) |
| Parent of origin (n=21) | 7 maternal, 7 paternal, 1 biparental — no bias detected | A | Choudhury et al. 2018 |
| Somatic in brain | detected across regions; showed the least instability, with higher methylation and lower expression | A | Parthaje et al. 2025, Cerebellum 24(3):60 — n = 1 brain |
| Biallelic carriers | CAG-45/45 and CAG-42/51; no difference from heterozygous CAG-51 | A | Srivastava et al. 2017, Brain 140(1):27–36 |
Teaching note. SCA12 is the counter-example to "repeat disease ⇒ anticipation ⇒ paternal bias." Current GeneReviews says the evidence for anticipation is insufficient, the only parent-of-origin dataset is 7-vs-7 in 21 patients, and the single brain studied showed least in the cerebellum — the opposite of the striatal pattern in Huntington disease. The mechanistic rules learned from HTT and DMPK do not transfer automatically.
SCA12 — mechanism evidence (nothing established)
| Claim | Status | Tier | Source |
|---|---|---|---|
| Repeat region has activity that increases with repeat length | demonstrated in reporter assays | A | O'Hearn et al. 2015, Mov Disord 30(13):1813–1824 |
| Repeat acts as a cis element up-regulating ; CREB1/SP1 up, TFAP4 down | demonstrated in cells | A | Lin et al. 2010, Hum Genet 128(2):205–212 |
| Expansion raises the 7B7D transcript and Bβ1 protein, and yields a polyserine tract that triggers apoptosis | demonstrated in cell models | A | Zhou et al. 2024, Mov Disord 39(10):1886–1891 |
| Most PPP2R2B isoforms are down-regulated in patient-derived mature neurons | demonstrated — contradicts the overexpression model | A | Kumar et al. 2024, iScience 27(5):109768 |
| Bβ2 targets to mitochondria and promotes apoptosis | demonstrated (overexpression) | A | Dagda et al. 2003, JBC 278(27):24976–24985 |
| Bβ2 dephosphorylates Drp1 S637, drives fission, antagonises neuronal survival; silencing Bβ2 is protective | demonstrated (overexpression/knockdown) | A | Dagda et al. 2008, JBC 283(52):36241–36248 |
| Drosophila ppp2r2b overexpression → neurodegeneration, mitochondrial fragmentation, ROS; rescued by antioxidants and SOD2 | demonstrated in fly | A | Wang et al. 2011, JBC 286(24):21742–21754 |
| The expansion specifically raises Bβ2 in patient neurons | not demonstrated — the repeat is 5′ to the Bβ1 first exon, not Bβ2's | — | inference from Dagda 2003 + Zhou 2023 |
| Nuclear CAG RNA foci in patient iPSC-derived neural stem cells; 13 proteins bind the expanded repeat exclusively | demonstrated | A | Kumar et al. 2024, iScience |
| CUG RNA foci from the antisense transcript PPP2R2B-AS1 | demonstrated in SK-N-MC cells | A | Zhou et al. 2023, Mov Disord 38(12):2230–2240 |
| at the SCA12 locus — polyQ and polySer (sense, Delhi group); polyAla (antisense, Hopkins group); polyLeu and polyCys absent | demonstrated in cells and iPSC neurons; frames not reconciled between labs | A | Kumar 2024; Zhou 2023 |
| Any RAN product in SCA12 human brain tissue | never shown | — | negative: Zhou 2023 could not reliably detect expanded transcript in one post-mortem brain |
| Tau dephosphorylation as an SCA12 mechanism | proposed in a 2001 review, never tested in any SCA12 system; the one autopsy series found tau-negative inclusions | — | Holmes et al. 2001, Brain Res Bull 56(3–4):397–403; O'Hearn et al. 2015 |
| Autopsy findings | enlarged ventricles, marked cerebral cortical atrophy, loss, less prominent cerebellar/pontine atrophy, ubiquitin-positive intranuclear inclusions negative for polyQ, α-synuclein, tau and TDP-43 | A | O'Hearn et al. 2015 — a handful of brains |
| Overall mechanism confidence | STRchive gene–disease evidence score 8.5 / 18 ("Moderate"); mechanism "incompletely established" | A | STRchive curation page, fetched 2026-08-25 |
Teaching note. SCA12 is the honest counterweight to the tidy repeat-disease narrative. Twenty-seven years after the gene was found, the field has five plausible mechanisms — promoter-driven overexpression, Bβ2-driven mitochondrial fission, sense RNA toxicity, antisense RNA toxicity, and RAN translation in at least three frames — supported almost entirely by overexpression constructs, cell lines, one fly model, iPSC neurons and a handful of autopsy brains. Two of the strongest results point in opposite directions (Bβ1 up in Zhou 2024, isoforms down in Kumar 2024). "We do not know" is the correct answer, and it is not a gap in the teaching — it is the lesson.
SCA12 — therapy and trial readiness
| Quantity | Value | Tier | Source |
|---|---|---|---|
| Published ASO or RNA-targeting therapeutic for | none | A | directed Europe PMC search, 2026-08-25, zero hits |
| Disease-modifying clinical trial in | none found | A | same search |
| Randomised trial of propranolol | n = 60, extended-release propranolol to 240 mg/day vs placebo, 8 weeks; significant reduction in TETRAS PS, improved ADL, SARA and SF-36; no safety discontinuations | A | Mohapatra et al. 2026, Mov Disord 41(2):373–383 |
| Longitudinal progression data | 3 patients over 5–6 yr; gait variability (step length, stance time, step time) progressed | A | Siddique et al. 2021, Clin Park Relat Disord 5:100102 |
| Objective motor biomarker | ML on reaching kinematics separates SCA12 from essential tremor at 83.3% accuracy | A | Bayen et al. 2026, 25(4):92 |
| Candidate plasma biomarker | Aβ40 decreased, Aβ42/Aβ40 ratio increased | A | Banerjee et al. 2026, Cerebellum 25(3):75 |
| Candidate blood transcript biomarker | 5 mitochondrial quality-control genes down in PBMCs | A | Ansari et al. 2026, Parkinsonism Relat Disord 145:108228 |
| Multi-site prospective natural-history cohort with annualised SARA rates | none found | A | directed search, 2026-08-25 |
Teaching note. SCA12 in 2026 has a positive randomised trial — of a beta-blocker for tremor. That is symptom control, not disease modification. The gap between "we can measure this disease well enough to run an RCT" and "we have anything to give it" is the entire distance between a trial-ready and a druggable mechanism.
SCA12 locus — genomic definition (GRCh38)
Source: Illumina ExpansionHunter hg38 variant catalog · fetched 2026-08-25 · Tier A
| Quantity | Value |
|---|---|
| Catalog entry (0-based half-open) | chr5:146878727-146878757, LocusStructure (GCT)* |
| Same interval, 1-based (samtools form) | chr5:146,878,728–146,878,757 (GRCh38) |
| Reference | 10 repeat units (30 bp) |
| v4 API main_reference_region (cross-check) | chr5:146878727-146878757 · fetched 2026-08-25 |
| STRchive interval (cross-check) | chr5:146878727-146878759 · strchive.org/loci/sca12_ppp2r2b |
The catalog motif GCT is the plus-strand reading; is transcribed from the minus strand, where the repeat reads CAG. STRchive annotates the repeat as 5'UTR; the gnomAD v4 API annotates the same interval "coding: polyserine" against a different transcript — which transcript the repeat is "in" is -dependent. Teach the disagreement.
Repeat-genotyping tools — versions and platforms
Source: GitHub releases API + bioconda package API, per-tool repos (ExpansionHunter, REViewer, ExpansionHunterDenovo, STRling, GangSTR, TRGT) · fetched 2026-08-25 · Tier A
| Quantity | Value |
|---|---|
| ExpansionHunter latest release | v5.0.0 (2021-08-20); bioconda incl. osx-arm64 |
| Loci in default hg38 catalog | 31, including |
| REViewer latest release | v0.2.7 (2022-02-02); repo archived; bioconda osx-64/linux only |
| ExpansionHunter Denovo latest | v0.9.0 (2020-03-04); bioconda linux only |
| STRling latest | v0.6.0 (2025-12-06); bioconda linux-64 only |
| GangSTR latest | v2.5 (2021-01-29); bioconda incl. osx-arm64 |
| TRGT latest | v5.1.0 (2026-06-10); bioconda linux-64 only |
Versions move; re-check dates before republishing. The archived status of REViewer is a teaching point about clinical-bioinformatics tool lifecycles, not a reason to drop it.
Lab-11 public data — URLs, sizes, executed results
Source: HEAD requests + executed samtools/ExpansionHunter runs on this machine · 2026-08-25 · Tier A
| Quantity | Value |
|---|---|
| HG00096 30x (AWS mirror) | 15.7 GB — https://1000genomes.s3.amazonaws.com/1000G_2504_high_coverage/data/ERR3240114/HG00096.final.cram |
| Its .crai index | 1.4 MB |
| Reads in chr5:146877000-146880000 (executed) | 888, all 150 bp; region 145 KB |
| ExpansionHunter of HG00096 at (executed) | 10/14 GCT units (CI 10-10/14-14; 12+14 spanning reads; 0 IRRs) |
| chr5 reference slice via EBI CRAM registry (REF_PATH) | 173 MB cached, fetched automatically by MD5 |
| Full GRCh38_full_analysis_set_plus_decoy_hla.fa (alternative) | 3.26 GB |
| HG002 HiFi GRCh38 BAM | 119.8 GB (bai 23.8 MB) — region extraction: 69 reads, mean 14,552 bp, 9 s |
| HG002 source material | DNA extracted from the EBV-immortalised B-lymphoblastoid cell line GM24385 (Coriell) — NIST RM 8391 certificate · Tier A |
| HG002 repeat by direct count (executed) | 53 spanning HiFi reads, modal 10 CTG units (≈10/10) |
| GIAB HG002 ONT-UL GRCh38 BAM | 187.5 GB (bai 54.6 MB) — 41 reads over the repeat, counted in 11 s |
| Whole-lab download budget | ≈300 MB |
samtools view -c <URL> regionworks with no reference (counting never decodes bases); extracting sequences from CRAM withoutREF_PATHfails withUnable to fetch reference— run the failure first, then setREF_PATH=...:https://www.ebi.ac.uk/ena/cram/md5/%s. Cohort: 3,202 samples at 30x, NovaSeq 2×150 bp (Byrska-Bishop 2022, Cell 185:3426).
PPP2R2B expression — GTEx v10
Source: GTEx v10 gene median TPM file (downloaded, 8.8 MB) and GTEx portal API v2 · fetched 2026-08-25 · Tier A
| Quantity | Value |
|---|---|
| Genes × tissue columns in the median- file | 59,033 × 68 (54 primary tissues + 14 LCM sub-columns) |
| median TPM, Brain_Frontal_Cortex_BA9 | 29.71 (highest tissue) |
| PPP2R2B median TPM, Brain_Cerebellum / Cerebellar_Hemisphere | 10.02 / 8.78 |
| PPP2R2B median TPM, Whole_Blood / Liver / Muscle_Skeletal | 0.40 / 0.05 / 0.04 |
| Annotated transcripts returned by the transcript API | 21; top cerebellar isoform ENST00000504198.5 at 6.26 TPM |
| Full transcript-TPM matrix (do NOT assign) | 4.34 GB; no median-transcript flat file exists in the v10 bucket |
GTEx v10 released Nov 2024 (AnVIL announcement); ~12% more samples than v8 (Tier B). Numbers above are v10 and will change with any future release — name the version wherever they appear.
Lab-12 single-cell data — Siletti human brain atlas
Source: CZ CELLxGENE curation API, collection 283d65eb-dd53-496d-adb7-7570c7caa443 · fetched 2026-08-25 · Tier A
| Quantity | Value |
|---|---|
| Atlas | Human Brain Cell Atlas v1.0 (Siletti et al. 2023, Science 382:eadd7046) |
| Cerebellar Vermis (CBV) dissection h5ad | 71,874 cells, 431 MB, direct download, no registration |
| lateral hemisphere (CBL) h5ad | 28,028 cells, 160 MB |
| Supercluster: Cerebellar inhibitory h5ad | 14,411 cells, 150 MB |
Direct URLs are content-addressed (datasets.cellxgene.cziscience.com/<id>.h5ad) and may rotate on dataset revision — re-resolve via the collection page if a 404 appears. The zero-install fallback is the cellxgene Explorer on the same collection.
What this review changed
Recorded so the corrections aren't silently re-introduced later:
- — Release 1 (47 genomes) is superseded by Release 2 (200+ individuals, 460 , May 2025).
- Sequencing platforms — Roche AXELIOS 1 / SBX launched June 2026 and belongs in the platform comparison.
- ACMG — v4 exists in draft; the 2015 guidelines need to be framed as "current but under active revision", not as settled.
- Gene count — pinned to the exact current (19,442, GENCODE 50) rather than a remembered round number, with the non-coding:coding ratio available to make a pedagogical point.
- UP element (2026-08-13) — ~30-fold, not tenfold, at rrnB P1. The old figure understated it 3×.
- σ⁵⁴ activators (2026-08-13) — 80–150 bp upstream, not "hundreds of base pairs".
- Pol III stoichiometry (2026-08-13) — three cores per live replisome; "dimeric holoenzyme" is the pre-2010 picture.
- Minor (2026-08-13) — U5 belongs in the parts list; it is shared with the major spliceosome.
- Lactase persistence (2026-08-13) — the sweep is not coupled to the onset of dairying; the stays rare for nearly three millennia after first appearing.
- GENCODE residual (2026-08-13) — the 1,096 genes outside the four headline categories are 412 IG/TR coding segments + 665 readthrough + 19 artifact, not "IG/TR gene segments" alone. 1,077 are protein-coding, so the do-not-subtract lesson stands; the identification was wrong. The 237 IG/TR are inside the 14,702, not additional to it.
- ONT accuracy (2026-08-13) — simplex ~Q26 (99.75%), vendor record Q28. The old ~Q23 ceiling was ~2.5 years stale on its own pinning date. The duplex ~Q30 figure now has no vendor page behind it.
- PacBio Revio throughput (2026-08-13) — ~100–120 Gb per SMRT Cell in ~24 h, not ~60–90 Gb in ~30 h. One chemistry generation behind.
- Roche SBX read length (2026-08-13) — ~400–600 bp short-read mode, up to ~1,500 bp; the pinned "~175 bp" was a pre-launch example figure and appears nowhere in Roche's shipped documentation.
- 10x multiplet rate (2026-08-13) — ~0.4% per 1,000 cells recovered on current chemistry, roughly half the 0.5–1% previously pinned. Worked examples in Chapter 48 recomputed.
- Human generation time (2026-08-13) — newly pinned at 27 years. It was unpinned, and the curriculum was silently using 25 (Ch 27), 28 (Ch 29) and 29 (problem set 9) for the same conversion. Chapters 27 and 29 now agree; the question banks and problem sets still need reconciling.
- ClinGen MYH7 VCEP (2026-08-13) — v2.0 (approved 2024) supersedes the Kelly 2018 v1 thresholds. PP3 is approved at Supporting only for MYH7, so Chapter 55's flagship worked example was applying the general REVEL calibration inside a case that obeys the specification elsewhere. PS2's specification default runs the other way (Moderate, not Supporting). Both now applied; the tally is unchanged at 6 points and Likely pathogenic, and the standing lesson is check for a specification before deriving your own thresholds.
- HCM gene contribution (2026-08-13) — MYBPC3 (~20%) is the largest single-gene contributor, not MYH7 (~14%). Chapter 55's g ≈ 0.30 was unsourced and wrong under the chapter's own definition of g; AF_max for HCM via MYH7 is 5.6 × 10⁻⁶ (~9 alleles in 1.6M), not 1.2 × 10⁻⁵ (~19).
- Erlich et al. 2018 (2026-08-13) — "~60% of US individuals of European descent at ~2% " fuses two different results and states a figure the paper does not contain. 60% is the hit rate for a 1.28M-record database (~0.9% coverage); at 2% coverage the paper projects >99%. Chapter 58 had back-solved its N ≈ 45 from the fused datum; the model is now presented as a shape argument with an explicitly effective, conservative N.
- ancestry denominator (2026-08-13) — European ancestry is ~16% of the world (Martin et al. 2019); 9% is Europe's resident population, and using it against an ancestry numerator inflated the over-representation ratio from ~5.4× to ~9.7×. Monitor figures re-fetched live: 88.25% European, 0.27% African.
- Nagoya Protocol (2026-08-13) — does not cover human genetic material. Listing it among remedies for the Havasupai structure of harm was a category error; Chapter 58 now says so explicitly rather than deleting it, because the mis-citation is common.
- Generation Study (2026-08-13) — >500 genes / 200+ conditions / ~1 in 100, superseding 462 / 208 / 1 in 200. Corrected in Ch 57 §4 and Ch 54 (Ch 54's "more than 200 conditions" was already right and was left alone).
- EU NGT regulation (2026-08-13) — adopted 17 June 2026. Chapter 57's "the EU still regulates most such organisms under its 2001 GMO directive" became false, and the section's "one technique, three regulatory philosophies" punchline went with it — the EU's two-tier, edit-based structure now parallels the UK Act.
- DOJ forensic-genealogy policy (2026-08-13) — Ch 58 said September 2019, Ch 57 said November 2019, and both were half-right: approved 2 September, effective 1 November. Both chapters now name the event rather than a bare date.
Both question-bank propagations of items 17 and 18 were resolved on 2026-08-13.
question-banks/qb-part-12.mdno longer back-solves N from the fabricated "60% at 2% coverage" datum; it now states the model as a shape argument and gives Erlich's two irreconcilable fits (N ≈ 107 at ~0.9% coverage, N ≈ 228 at 2%), matching Ch 58.question-banks/qb-part-11.mdnow carries 5.6 × 10⁻⁶ / ~9 alleles and names MYBPC3 as the largest single-gene contributor, matching Ch 55.
Re-verification
Everything above carries a verification date of 2026-08-10, except rows and sections explicitly dated 2026-08-13 (added during the adjudicated accuracy pass). The Tier C rows (sequencing platforms) and the ACMG row are the ones that will rot first. Re-check them before relying on this curriculum a year from now.
The 2026-08-13 pass found that prediction was already too optimistic. Two of the four sequencing-platform rows and the single-cell multiplet rate were stale on their original 2026-08-10 pinning date — the ONT figure by about two and a half years. A vendor row is not verified because someone wrote a date next to it; it is verified because someone opened the vendor's page. That is why the Tier C rows now carry their own per-row URL and fetch date: the next person to re-check them can see exactly what was opened and when, and does not have to trust a section-level date stamp.